Economic Burden Of Highly Active Relapsing-Remitting Multiple Sclerosis Patients In The French National Health Insurance Database

Background As healthcare management of highly active-relapsing-remitting multiple sclerosis (HA-RRMS) patients is more complex than for the whole multiple sclerosis (MS) population, this study assessed the related economic burden from a National Health Insurance's (NHI's) perspective. Research design and methods Study based on French NHI databases, using individual data on billing and reimbursement of outpatient and hospital healthcare consumption, paid sick leave and disability pension, over 2010-2017. Results Of the 9,596 HA-RRMS adult patients, data from 7,960 patients were analyzed with at least 2 years of follow-up. Mean annual cost/patient was euro29,813. Drugs represented 40% of the cost, hospital care 33%, disability pensions 9%, and all healthcare professionals' visits combined 8%. Among 3,024 patients under 60 years-old with disability pension, disability pension cost euro7,168/patient/year. Among 3,807 patients with paid sick leave, sick leave cost euro1,956/patient/year. Mean costs were euro2,246/patient higher the first year and increased by euro1,444 between 2010 and 2015, with a euro5,188 increase in drug-related expenditures and a euro634 increase in healthcare professionals' visits expenditures but a euro4,529 decrease in hospital care expenditures. Conclusions The cost of health care sick leaves, and disability pensions of HA-RRMS patients was about twice as high as previously reported cost of MS patients.